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MaOBJECTIVES The purpose of this study was to prospectively investigate the diagnostic and prognostic impact of
cardiac magnetic resonance (CMR) T1 mapping and validate it against left ventricular biopsies.
BACKGROUND Extracellular volume (ECV) expansion is a key feature of heart failure. CMR T1 mapping has been
developed as a noninvasive technique to estimate ECV; however, the diagnostic and prognostic impacts of this technique
have not been well established.
METHODS A total of 473 consecutive patients referred for CMR (49.5% female, age 57.8  17.1 years) without
hypertrophic cardiomyopathy, cardiac amyloidosis, or Anderson-Fabry disease were studied. T1 mapping with the
modiﬁed Look-Locker inversion recovery (MOLLI) sequence was used for ECV calculation (CMR-ECV). For methodological
validation, 36 patients also underwent left ventricular biopsy, and ECV was quantiﬁed by TissueFAXS analysis
(TissueFAXS-ECV). To assess the prognostic value of CMR-ECV, its association with hospitalization for cardiovascular
reasons or cardiac death was tested in a multivariable Cox regression model.
RESULTS TissueFAXS-ECV was 26.3  7.2% and was signiﬁcantly correlated with CMR-ECV (r ¼ 0.493, p ¼ 0.002).
Patients were followed up for 13.3  9.0 months and divided into CMR-ECV tertiles for Kaplan-Meier analysis (tertiles
were #25.7%, 25.8% to 28.5%, and $28.6%). Signiﬁcantly higher event rates were observed in patients with higher
CMR-ECV (log-rank p ¼ 0.013). By multivariable Cox regression analysis, CMR-ECV was independently associated with
outcome among imaging variables (p ¼ 0.004) but not after adjustment for clinical parameters.
CONCLUSIONS CMR T1 mapping allows accurate noninvasive quantiﬁcation of ECV and is independently associated
with event-free survival among imaging parameters. Its prognostic value on top of established clinical risk factors
warrants further investigation in long-term studies. (J Am Coll Cardiol Img 2016;9:14–23) © 2016 by the American
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AB BR E V I A T I O N S
AND ACRONYM S
CABG = coronary artery
bypass graft
CMR = cardiac magnetic
resonance
ECV = extracellular volume
LGE = late gadolinium
enhancement
LV = left ventricular
MOLLI = modiﬁed Look-Locker
inversion
NT-proBNP = N-terminal
prohormone brain natriuretic
peptide
right ventricular
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15approaches have been studied (16); however, native
T1 mapping and the calculation of ECV by use of
native and post-contrast T1 maps have been
described as the most promising measures of extra-
cellular matrix expansion (11).
Native T1 mapping identiﬁes pathological changes
affecting the intracellular or extracellular space, such
as myocardial edema in acute myocardial infarction
or in myocarditis (17–19), amyloid deposition (20,21),
iron overload (22), or glycosphingolipid storage
in Anderson-Fabry disease (23). With the use of T1
maps before and after administration of gadolinium-
based contrast agents, the ECV can be estimated (8).
Elevated ECV as quantiﬁed by CMR (CMR-ECV) has
been demonstrated in cardiac amyloidosis (24–26),
acute myocarditis (27), and hypertrophic cardiomy-
opathy sarcomere mutation carriers, even in the
absence of myocardial hypertrophy (28). Several
clinical trials are currently investigating the potential
role of T1 mapping in various clinical settings, such as
timing of surgery in aortic stenosis (NCT01755936), or
are evaluating the cardiotoxic effects of chemo-
therapy (NCT01719562) (29).SEE PAGE 24However, despite a rapidly growing body of
evidence indicating the clinical usefulness of this
novel technique, its prognostic signiﬁcance is still not
well deﬁned. Furthermore, although inversion re-
covery methods such as the modiﬁed Look-Locker
inversion recovery (MOLLI) sequence demonstrate
excellent precision and are highly reproducible when
tightly controlled protocols are used (30), no ﬁnal
consensus has yet been reached concerning a
preferred T1-mapping technique (11). Its reliability is
also limited by a lack of validation data against in vivoTABLE 1 Overview of Studies Validating Various T1-Mapping Method
First Author (Ref. #) T1-Mapping Method
Flett et al. (8) EQ-CMR ECV 18 AS an
Fontana et al. (33) ShMOLLI EQ ECV
Multiple breath-hold ECV
18 AS p
White et al. (37) ShMOLLI single-bolus ECV
ShMOLLI EQ ECV
18 AS p
Bull et al. (32) ShMOLLI native T1 19 AS p
Miller et al. (36) DynEq-CMR MOLLI ECV 6 Expla
Iles et al. (34) Multiple breath-hold post contrast 9 Patien
Mascherbauer et al. (13) Multiple breath-hold post contrast 9 Patien
Iles et al. (35) Multiple breath-hold post contrast 4 Explan
8 patien
Aus dem Siepen et al. (31) MOLLI ECV 24 Patie
AS ¼ aortic stenosis; CMR ¼ cardiac magnetic resonance; DCM ¼ dilated cardiomyopathy
cardiomyopathy; (Sh)MOLLI ¼ (shortened) modiﬁed Look-Locker inversion recovery seqmyocardial biopsies because of heterogeneity
of techniques and small patient numbers
(Table 1) (8,9,13,31–37). Although T1-mapping
data appear to have great prognostic poten-
tial, only a few studies have reported on the
prognostic impact of T1 mapping by CMR
(13,38–41).
The present study prospectively evaluates
the diagnostic and prognostic signiﬁcance of
CMR T1 mapping for ECV calculation in 473
consecutive patients, of whom 36 underwent
left ventricular (LV) biopsy for methodolog-
ical validation.
METHODSSTUDY DESIGN. This was a prospective, observational
study performed at the Medical University of Vienna,
approved by the local ethics committee. Between July
2012 and February 2015, 473 consecutive patients
without hypertrophic cardiomyopathy, cardiac
amyloidosis, or Anderson-Fabry disease referred for
CMR were invited to participate. Those patients who
also underwent coronary angiography were invited to
undergo myocardial biopsy. Written informed consent
was collected before study enrollment from all pa-
tients. The Medical University of Vienna represents a
university-afﬁliated tertiary care center with a high-
volume multimodality-imaging facility.
CLINICAL DEFINITIONS. At the time of CMR, de-
mographic data (age, sex, body mass index, body
surface area) and comorbidities were assessed. These
included atrial ﬁbrillation (documented episode dur-
ing the previous 6 months), arterial hypertension
($140/90 mm Hg or antihypertensive treatment),
hypercholesterolemia (total serum cholesterol 240
RV =s Against Histological Specimens
Patient Population r and p Values
d 8 HCM patients r2 ¼ 0.796, p < 0.001
atients r2 ¼ 0.685, p < 0.001
r2 ¼ 0.589, p < 0.001
atients r2 ¼ 0.69, p < 0.001
r2 ¼ 0.71, p < 0.001
atients r ¼ 0.655, p ¼ 0.002
nted hearts r2 ¼ 0.893, p ¼ 0.004
ts with heart failure after orthotopic heart transplantation r ¼ –0.70, p ¼ 0.003
ts with heart failure and preserved ejection fraction r ¼ 0.977, p < 0.001
ted hearts;
ts with myectomy for HCM
r ¼ 0.78, p ¼ 0.003
nts with DCM r ¼ 0.85, p < 0.01
; DynEq ¼ dynamic equilibrium; ECV ¼ extracellular volume; EQ ¼ equilibrium; HCM ¼ hypertrophic
uence.
TABLE 2 Baseline Clinical and CMR Parameters
All Patients
(N ¼ 473)
CMR-ECV <27.0%
(n ¼ 237; 50.1%)
CMR-ECV $27.0%
(n ¼ 236; 49.9%) p Value
Clinical parameters
Age, yrs 0.001
Mean  SD 57.8  17.1 55.3  17.0 60.4  16.9
Median (IQR) 61.3 (45.9–71.6) 56.8 (43.6–68.9) 65.7 (47.7–73.2)
Female 49.5 40.9 58.1 <0.001
BMI, kg/m2 0.037
Mean  SD 27.5  5.6 27.9  5.2 27.1  5.9
Median (IQR) 26.9 (23.7–30.6) 27.3 (24.5–30.8) 26.3 (22.9–30.1)
Hypertension 70.8 62.8 78.3 0.001
Atrial ﬁbrillation 28.3 17.2 38.6 <0.001
Diabetes 17.0 14.9 19.0 0.273
Hyperlipidemia 41.6 43.9 39.5 0.376
Current smoker 22.4 18.8 25.3 0.185
Hospitalized at time of CMR 27.2 27.5 26.9 0.904
CAD 27.4 31.9 23.3 0.056
Previous PCI 10.9 13.4 8.7 0.132
Previous CABG 4.3 5.3 3.4 0.349
Previous MI 10.4 12.8 8.2 0.129
Previous stroke 3.6 3.2 3.9 0.711
eGFR, ml/min/1.73 m2 0.040
Mean  SD 78.2  25.4 81.1  24.2 75.5  26.2
Median (IQR) 76.6 (61.0–94.4) 80.1 (63.8–95.5) 74.4 (55.9–93.4)
Serum NT-proBNP, pg/ml <0.001
Mean  SD 1,847  3,274 583  1,817 1,738  4,110
Median (IQR) 285 (95–1,050) 160 (45–413) 645 (182–1,761)
Follow-up, months 0.875
Mean  SD 13.3  9.0 13.3  9.6 13.3  8.5
Median (IQR) 12.2 (4.0–21.7) 11.3 (3.8–22.8) 13.1 (4.5–20.5)
Referral diagnosis 0.002
Heart failure 52.0 43.9 60.2
VHD 19.9 21.1 18.6
CAD 11.6 14.8 8.5
Others 16.5 20.3 12.7
Continued on the next page
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16mg/dl or use of cholesterol-lowering medication),
diabetes (fasting blood glucose level >126 mg/dl or
use of antidiabetic medication), coronary artery dis-
ease (coronary artery stenosis >50% or fractional
ﬂow reserve <0.8), previous percutaneous coronary
intervention, and previous coronary artery bypass
grafting (CABG). Previous myocardial infarction was
deﬁned by both history and CMR. The estimated
glomerular ﬁltration rate was calculated with the
simpliﬁed Modiﬁcation of Diet in Renal Disease
formula (42).
OUTCOME MEASURES. All patients were prospec-
tively followed up at 6-month intervals by am-
bulatory visits or telephone calls in case of
immobility. The primary endpoint was deﬁned as
a composition of hospitalization for cardiovascular
reasons (heart failure, acute coronary syndrome,pulmonary embolism, stroke) or cardiac death.
Endpoints were adjudicated by our internal adju-
dication committee (D.B. and C.Z.-T.), blinded to
CMR data.
CMR. All patients underwent CMR examinations
on a 1.5-T scanner (MAGNETOM Avanto, Siemens
Healthcare GmbH, Erlangen, Germany), which con-
sisted of standard protocols that included late gad-
olinium enhancement (LGE) (0.1 mmol/kg gadobutrol
[Gadovist, Bayer Vital GmbH, Leverkusen, Germany])
if the estimated glomerular ﬁltration rate was
>30 ml/min/1.73 m2. Left and right atrial volumes
were assessed by the biplane area-length method
(43). At the time of insertion of the intravenous
cannula, blood was drawn for hematocrit and serum
creatinine level measurement. LGE was quantiﬁed
on short-axis stacks using a semiautomatic approach
TABLE 2 Continued
All Patients
(N ¼ 473)
CMR-ECV <27.0%
(n ¼ 237; 50.1%)
CMR-ECV $27.0%
(n ¼ 236; 49.9%) p Value
CMR parameters
LA volume <0.001
Mean  SD 111.3  75.0 99.4  73.2 123.5  75.1
Median (IQR) 93.3 (69.7–133.6) 86.6 (64.3–113.5) 105.7 (76.8–155.2)
RA volume 0.037
Mean  SD 95.0  60.8 87.9  55.7 102.3  65.0
Median (IQR) 81.0 (63.4–106.5) 79.8 (60.3–101.0) 82.8 (65.8–113.9)
IVS, mm 0.568
Mean  SD 11.5  2.7 11.5  2.5 11.4  3.0
Median (IQR) 11.0 (10.0–13.0) 11.0 (10.0–13.0) 11.0 (9.5–13.0)
LV mass, g 0.092
Mean  SD 114.4  41.2 119.5  43.5 110.5  39.1
Median (IQR) 102.5 (86.0–136.5) 113.0 (90.0–144.0) 97.0 (85.0–125.0)
LVEF 0.511
Mean  SD 61.5  11.8 62.2  10.6 60.9  12.9
Median (IQR) 62.0 (56.0–69.0) 63.0 (56.0–69.0) 62.0 (55.0–69.0)
LVEDVi, ml 0.324
Mean  SD 77.5  25.0 75.7  22.4 79.3  27.4
Median (IQR) 71.7 (60.0–88.3) 70.7 (59.8–87.1) 72.5 (60.4–89.6)
Cardiac index, l/min 0.168
Mean  SD 3.1  0.9 3.2  0.9 3.1  0.9
Median (IQR) 3.0 (2.6–3.5) 3.0 (2.6–3.6) 2.9 (2.5–3.4)
RVEF 0.661
Mean  SD 56.2  10.1 56.8  9.2 55.5  10.9
Median (IQR) 57.0 (50.0–63.0) 57.0 (51.0–62.0) 57.0 (49.0–63.0)
RVEDVi, ml 0.104
Mean  SD 76.8  21.1 75.0  18.4 78.6  23.4
Median (IQR) 73.9 (63.3–86.3) 72.6 (62.0–85.4) 76.1 (64.7–86.7)
Infarct size, % of LV mass* 0.931
Mean  SD 15.5  6.4 14.8  4.6 16.3  8.0
Median (IQR) 14.5 (10.8–19.0) 15.0 (12.0–17.0) 14.0 (10.0–19.0)
CMR-ECV <0.001
Mean  SD 27.5  3.9 24.6  1.9 30.4  3.2
Median (IQR) 27.0 (25.1–29.4) 25.1 (23.6–26.2) 29.4 (28.1–31.6)
Values are mean  SD, median (interquartile range), or %. *Among patients with myocardial infarction.
BMI ¼ body mass index; CABG ¼ coronary artery bypass graft surgery; CAD ¼ coronary artery disease; CMR ¼ cardiac magnetic resonance; CMR-ECV ¼ extracellular volume
as determined by cardiac magnetic resonance imaging; eGFR ¼ estimated glomerular ﬁltration rate; IQR ¼ interquartile range; IVS ¼ interventricular septal thickness; LA ¼ left
atrium; LGE ¼ late gadolinium enhancement; LV ¼ left ventricle; LVEDVi ¼ left ventricular end-diastolic volume indexed to body surface area; LVEF ¼ left ventricular ejection
fraction; MI ¼myocardial infarction; NT-proBNP ¼ N-terminal prohormone brain natriuretic peptide; PCI ¼ percutaneous coronary intervention; RA ¼ right atrium; RVEF ¼ right
ventricular ejection fraction; RVEDVi ¼ right ventricular end-diastolic volume indexed to body surface area; VHD ¼ valvular heart disease.
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17by deﬁning a threshold of 5 SD above mean signal
intensity of healthy myocardium (44).
T1 mapping was performed with electrocardio-
graphically triggered MOLLI with a 5(3)3 prototype
(5 acquisition heartbeats followed by 3 recovery
heartbeats and a further 3 acquisition heartbeats) on
a short-axis midcavity slice and with a 4-chamber
view. This method generates an inline, pixel-based
T1 map by acquiring a series of images over several
heartbeats with shifted T1 times, inline motion
correction, and inline calculation of the T1 relaxa-
tion curve within 1 breath hold. T1-sequence pa-
rameters were as follows: starting inversion time(TI) 120 ms, TI increment 80 ms, reconstructed ma-
trix size 256  218, measured matrix size 256  144
(phase-encoding resolution 66%, phase-encoding
ﬁeld of view 85%). T1 maps were created both
before and 15 min after contrast agent application.
For post-contrast T1 mapping, a 4(1)3(1)2 prototype
was used. Regions of interest were deﬁned as
LV myocardium without areas of infarcted myocar-
dium. T1 values (in milliseconds) of the blood pool
were derived with sufﬁcient distance to papillary
muscles and the endomyocardial border. T1 values
from the short-axis and the 4-chamber view were
averaged.
FIGURE 2 Patient
Heart Failure*
n = 246
A total of 473 patien
assessment of extrac
patients with preserv
muscular dystrophy
(n ¼ 4), and aortic a
FIGURE 1 Cardiac Magnetic Resonance T1 Map and Left Ventricular Histological Specimen
(A) Native T1 map in a patient with heart failure and preserved ejection fraction. Extracellular volume by cardiac magnetic resonance T1
mapping was 26.5%. (B) Left ventricular histological specimen of the same patient scanned with TissueFAXS software. (C) Same specimen after
a color-threshold approach was used to visualize and quantify extracellular matrix (30.7%).
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18CMR-ECV was calculated with the formula (15)
CMR ECV ¼
ð1 hematocritÞ 

1
T1 myo post



1
T1 myo pre


1
T1 blood post



1
T1 blood pre

where T1 myo pre/T1 blood pre indicates myocardial/
blood native T1 times and T1 myo post/T1 blood post
indicates T1 times of myocardium/blood 15 min afterPopulation
Referral Diagnosis
473 Patients
with ECV
Measurements
Other**
n = 78
Valvular Heart Disease
n = 94
Coronary Artery Disease
n = 55
ts underwent cardiac magnetic resonance imaging that included
ellular volume (ECV). Referral diagnoses are displayed. *Included
ed and reduced ejection fraction. **Sarcoidosis (n ¼ 45), Duchenne
gene carriers (n ¼ 21), pericardial effusion (n ¼ 6), cardiac tumors
neurysm (n ¼ 2).contrast agent application. Figure 1A shows a T1 map
of a heart failure patient.
For further CMR analyses dedicated software
(cmr42, Circle Cardiovascular Imaging Inc., Calgary,
Alberta, Canada) was used.
MYOCARDIAL BIOPSY AND HISTOLOGICAL ANALYSIS.
Biopsy samples were taken from the LV free wall
during left-sided heart catheterization by use of
dedicated devices (Bipal biopsy forceps, Cordis Cor-
poration, Bridgewater, New Jersey). Specimens were
embedded in parafﬁn, stained with modiﬁed tri-
chrome as described previously (45), and scanned
at 20-fold magniﬁcation with a high-resolution
microscope and TissueFAXS software (TissueG-
nostics, Vienna, Austria). ECV determined by this
method (TissueFAXS-ECV) was quantiﬁed with
ImageJ software (46) with a color-threshold macro
based on an algorithm by G. Landini (version 1.12) (47).
Endocardium, blood vessels, and perivascular tissue
were excluded from the analysis. Figure 1B shows a
histological specimen of a patient with heart failure;
Figure 1C displays TissueFAXS-ECV in the same spec-
imen after the exclusion of cardiomyocytes.
STATISTICAL ANALYSIS. Continuous data are
expressed as mean  SD or as median with corre-
sponding interquartile range, and categorical vari-
ables are presented as percentages or total numbers.
Differences between 2 groups were analyzed with the
Wilcoxon rank sum test. Chi-square tests or Fisher
exact tests were used for categorical variables as
appropriate.
FIGURE 3 Correlation Between ECV by Cardiac Magnetic Resonance T1 Mapping and
TissueFAXS Analysis
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Correlation between extracellular volume (ECV) by cardiac magnetic resonance T1 mapping
(CMR-ECV) and by TissueFAXS (Tissue-FAXS ECV) in 36 left ventricular specimens
(r ¼ 0.493, p ¼ 0.002).
FIGURE 4 Bland-Altman Plot Demonstrating Good Agreement of TissueFAXS-ECV
and CMR-ECV
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Mean difference was 2.3% (limits of agreement: 14.7% and 10.0%). CMR-ECV ¼
extracellular volume as determined by cardiac magnetic resonance imaging T1 mapping;
TissueFAXS-ECV ¼ extracellular volume as determined by TissueFAXS.
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19Survival analyses were performed by Kaplan-
Meier estimates and Cox regression analysis. All
parameters with a signiﬁcant inﬂuence in the uni-
variable model entered the multiple regression
analysis by use of a stepwise selection. The multi-
variable model was run for clinical and imaging pa-
rameters separately. Clinical and imaging parameters
independently associated with outcome were
entered into an additional combined multivariable
model.
Pearson correlation coefﬁcients were used to
report the relationship between CMR and histological
ﬁndings. By Bland-Altman plots, agreement between
CMR-ECV and TissueFAXS-ECV was visualized and
reported as mean difference and corresponding 95%
conﬁdence interval (1.96 SD). For all tests, the
signiﬁcance level was set to p # 0.05.
RESULTS
BASELINE CHARACTERISTIC AND CMR PARAMETERS.
A total of 473 patients (49.5% female, age 57.8  17.1
years) were included. Table 2 lists patient baseline
characteristics and imaging parameters stratiﬁed ac-
cording to median CMR-ECV (27.0%). Patients with
higher ECV were more often female (p < 0.001), older
(p ¼ 0.001), more frequently hypertensive (p ¼
0.001), and in atrial ﬁbrillation (p < 0.001).
Furthermore, they had worse renal function
(p ¼ 0.040) and higher serum levels of N-terminal
prohormone brain natriuretic peptide (NT-proBNP;
p < 0.001) and presented with larger left and right
atrial volumes (p < 0.001 and p ¼ 0.037, respec-
tively). Referral diagnoses are shown in Figure 2.
CORRELATION BETWEEN ECV BY HISTOLOGY AND
CMR. Thirty-six patients underwent LV biopsy. Of
these, 28 had heart failure and 8 had valvular heart
disease. No LGE was present in the LV free wall where
biopsy samples were taken.
TissueFAXS-ECV was 26.3  7.2% on average.
CMR-ECV was signiﬁcantly correlated with histolog-
ical ECV (Figure 3) (r ¼ 0.493, p ¼ 0.002). Bland-
Altman analysis (Figure 4) revealed acceptable
agreement between CMR-ECV and TissueFAXS-ECV,
with a mean difference of 2.3% (limits of agree-
ment: 14.7% and 10.0%) between CMR-ECV and
TissueFAXS-ECV. There was a proportional bias
because of a higher variability of TissueFAXS-ECV
(interquartile range: 13.7% to 38.7%; 26.3  7.2%)
than CMR-ECV (interquartile range: 23.6% to 35.5%;
28.6  2.9%). Therefore, CMR-ECV measurements
tended to exceed the TissueFAXS-ECV measure-
ments for low average values, whereas the opposite
was the case for high average values.
FIGURE 5 Kaplan-Meier Plot for Event-Free Survival, Stratiﬁed by Tertiles
of CMR-ECV
100
80
60
40
20
0
Ev
en
t-f
re
e 
Su
rv
iv
al
 (%
)
Follow-up (Months)
CMR-ECV
20.0 30.025.0 35.0
Lowest Tertile:
≤ 25.7%
Middle Tertile:
25.8 - 28.5%
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Log-rank test, p ¼ 0.013. CMR-ECV ¼ extracellular volume as determined by cardiac
magnetic resonance imaging T1 mapping.
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20OUTCOME ANALYSIS. Patients were followed up for
13.3  9.0 months. Follow-up was complete in all
patients. In total, 71 patients (15.0%) experienced a
cardiac event (60 hospitalizations for cardiovascular
reasons, 11 cardiac deaths). The following parameters
were signiﬁcantly different between patients with
and without cardiac events (Online Table 1): patients
with events were older (p < 0.001); more frequently
had arterial hypertension (p < 0.001), atrial ﬁbrilla-
tion (p < 0.001), diabetes (p ¼ 0.016), and hyperlip-
idemia (p ¼ 0.036); and were more often hospitalized
at the time of CMR (p ¼ 0.004). They furthermore
presented with more frequent coronary artery disease
(p ¼ 0.027), previous CABG (p ¼ 0.001), previous
myocardial infarction (p ¼ 0.047), worse renal func-
tion (p ¼ 0.001), higher serum NT-proBNP levels (p <
0.001), a thicker interventricular septum (p ¼ 0.006),
and more dilated left and right atria (p ¼ 0.007 and
p ¼ 0.001, respectively). Cardiac index was worse
among patients with cardiac events (p ¼ 0.010), and
CMR-ECV was signiﬁcantly higher (p < 0.001).
By Kaplan-Meier analysis (Figure 5), higher CMR-
ECV was associated with an increased event rate
(log-rank test p ¼ 0.013). Table 3 displays results of
the univariable and multivariable Cox regression
analysis. Among clinical parameters with signiﬁcant
inﬂuence in the univariable model, age (p ¼ 0.008),
atrial ﬁbrillation (p ¼ 0.004), and previous CABG (p ¼
0.048) were independently associated with outcome.Among imaging variables, right ventricular (RV) size
(p ¼ 0.007), and CMR-ECV (p ¼ 0.004) remained
signiﬁcantly related to event-free survival in the
multivariable Cox regression analysis. When clinical
and imaging parameters were included in a combined
model, only age (p ¼ 0.001), atrial ﬁbrillation
(p ¼ 0.035), previous CABG (p ¼ 0.033), and RV size
(p ¼ 0.004) were independently associated with
outcome (Table 4).
DISCUSSION
The present study evaluated the diagnostic accuracy
and prognostic value of CMR-ECV. We have demon-
strated that ECV calculation by CMR T1 mapping
accurately reﬂects the actual amount of extracellular
matrix expansion by histology and provided evidence
for the prognostic and diagnostic usefulness of this
novel technique in a large and well-characterized
patient cohort.
CMR T1 mapping has recently awakened great
hope because it allows quantitative myocardial tissue
characterization (11,14,15,20,22,34,48). It has been
advertised as an important diagnostic tool in patients
with cardiac amyloidosis, inwhich high native T1 times
and ECV by CMR are found (21,25), as well as in
Anderson-Fabry disease, which is characterized by low
myocardial native T1 times (23). In addition, for acute
myocarditis, promising results have been published,
indicating more precise detection of the disease by T1
mapping than by conventional CMR (49,50).
HISTOLOGICAL VALIDATION OF T1-MAPPING
TECHNIQUES. Considerable efforts have been under-
taken to validate T1 mapping (8,9,13,31–37). Table 1
summarizes previous studies that reported validation
data of CMR T1 mapping against myocardial biopsy
samples. Various T1-mapping techniques have been
applied, including equilibrium contrast T1 mapping
(8,33,36,37), shortened MOLLI single bolus (37),
shortened MOLLI native T1 (32), and multiple breath-
hold post-contrast T1 mapping (13,34,35). Most of
these studies included small patient numbers. The
various T1-mapping techniques further limit their
comparability; however, all studies indicate that the
amount of ECV detected by T1 maps reﬂects actual
extracellular matrix expansion and/or disease
severity. The present investigation adds substantially
to the existing evidence because it provides validation
data from 36 patients who underwent in vivo LV bi-
opsy. Our data show good correlation and agreement
between ECV as calculated by CMR T1 mapping and
ECV by TissueFAXS from histology (Figures 3 and 4).
ECV BY T1 MAPPING: A RELIABLE PROGNOSTIC
MARKER? So far, little is known about the prognostic
TABLE 3 Univariable and Multivariable Cox Regression Analysis With Stepwise Selection
Univariable Multivariable
p Value HR (95% CI) p Value HR (95% CI)
Clinical parameters
Age <0.001 1.054 (1.035–1.073) 0.008 1.030 (1.008–1.053)
Female 0.877 1.038 (0.651–1.654)
BMI 0.070 1.034 (0.997–1.073)
Hypertension 0.001 3.685 (1.765–7.692)
Atrial ﬁbrillation <0.001 3.587 (2.237–5.752) 0.004 2.208 (1.282–3.803)
Diabetes 0.043 1.723 (1.018–2.916)
Hyperlipidemia 0.092 1.497 (0.936–2.395)
Current smoker 0.639 1.150 (0.641–2.065)
Hospitalized at time of CMR 0.023 1.732 (1.079–2.781)
CAD 0.057 1.593 (0.986–2.573)
Previous PCI 0.104 1.674 (0.899–3.117)
Previous CABG 0.003 3.013 (1.442–6.294) 0.048 2.228 (1.008–4.924)
Previous MI 0.111 1.657 (0.890–3.083)
Previous stroke 0.410 1.529 (0.557–4.194)
eGFR <0.001 0.981 (0.971–0.991)
Serum NT-proBNP* <0.001 1.812 (1.431–2.294)
Imaging parameters
LA volume 0.011 1.003 (1.001–1.005)
RA volume <0.001 1.005 (1.002–1.007)
IVS 0.029 1.186 (1.008–1.169)
LV mass 0.388 0.995 (0.985–1.006)
LVEF 0.710 1.004 (0.983–1.026)
LVEDVi 0.930 1.000 (0.990–1.009)
Cardiac index 0.056 0.749 (0.557–1.007)
RVEF 0.163 0.983 (0.960–1.007)
RVEDVi 0.001 1.015 (1.006–1.023) 0.007 1.012 (1.003–1.021)
Infarction size† 0.539 0.958 (0.837–1.098)
CMR-ECV <0.001 1.108 (1.053–1.165) 0.004 1.092 (1.028–1.160)
Analyses were run for clinical and imaging variables separately. *NT-proBNP was graded into quartiles for this
analysis. †Per 1% increase among patients with previous MI.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 2.
TABLE 4 Multivariable Cox Regression Analysis Including Clinical and Imaging Variables
That Were Signiﬁcant Within the Respective Group in the Multivariable Analysis
(Table 3) in a Model Using Forced Entry
p Value HR (95% CI)
Combined: Multivariable
p Value HR (95% CI)
Clinical: Multivariable
Age 0.008 1.030 (1.030–1.053) 0.001 1.033 (1.013–1.054)
Atrial ﬁbrillation 0.004 2.208 (1.282–3.803) 0.035 1.815 (1.042–3.164)
Previous CABG 0.048 2.228 (1.008–4.924) 0.033 2.261 (1.067–4.788)
Imaging: Multivariable
RVEDVi 0.007 1.012 (1.003–1.021) 0.004 1.011 (1.004–1.019)
CMR-ECV 0.004 1.092 (1.028–1.160) 0.497 1.022 (0.960–1.087)
Abbreviations as in Table 2.
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21value of ECV by CMR T1 mapping, a question that
has only been addressed in a few published series.
We previously showed that extracellular matrix
expansion, reﬂected by shorter multiple breath-hold
post-contrast T1 times, was associated with an in-
creased adverse event rate in patients with heart
failure with preserved ejection fraction (13). Wong
et al. (38) investigated 793 patients without cardiac
amyloidosis or hypertrophic cardiomyopathy; they
reported a signiﬁcant impact of ECV by CMR T1
mapping on outcome after adjusting for age, LV
ejection fraction, and infarction size. Ghosn et al. (39)
recently presented preliminary data on an
independent association between CMR-ECV and
event-free survival in 1,247 patients. Neilan et al. (40)
studied 145 patients with recurrent atrial ﬁbrillation
undergoing pulmonary vein isolation and found that
CMR-ECV was associated with worse outcome.
The present study evaluates the prognostic value of
CMR-ECV in 473 consecutive patients after correction
for a large number of cardiovascular comorbidities,
listed in Table 3. Importantly, NT-proBNP serum level,
renal function, atrial ﬁbrillation, and previous heart
surgery, as well as imaging parameters such as left and
right atrial and RV size, which have not been analyzed
previously in the context of CMR T1 mapping, were
included. Among imaging variables, CMR-ECV and RV
size were independently associated with outcome.
However, when clinical variables were included in the
Coxmodel, only age, atrial ﬁbrillation, previous CABG,
and RV size but not CMR-ECV remained signiﬁcantly
associated with event-free survival. To clarify whether
differences between our results and the ﬁndings by
Wong et al. (38) may be due to the inclusion of more
clinical variables, we restricted a second analysis to
only those variables that were assessed by Wong et al.
(38) (age, CMR-ECV, LV ejection fraction, and infarct
size). In that analysis, CMR-ECV was also indepen-
dently associated with survival among clinical vari-
ables in our cohort. Thus, discrepancies between
previous studies (38,39) and our results appear to arise
from the inclusion of additional clinical parameters.
FUTURE OUTLOOK. T1 mapping certainly has the
potential to provide insights into pathogenic pro-
cesses, to detect diseases at a very early stage, non-
invasively monitor disease progress, or even guide
therapy. New applications of T1 mapping currently
being investigated include monitoring the cardiotoxic
effects of chemotherapy (NCT01719562) and cardiac
involvement in human immunodeﬁciency virus–pos-
itive individuals (NCT02054494) (29). Further work
over long follow-up periods will be needed to in-
crease our knowledge about the prognostic impact of
T1 mapping in various diseases.STUDY LIMITATIONS. The data presented have been
collected in a single-center setting. Therefore, a
center-speciﬁc bias cannot be excluded. However,
the major advantages of limiting data collection to a
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
T1 mapping by CMR allows accurate noninvasive
estimation of ECV when compared with myocardial
biopsies. Among imaging parameters, T1 mapping has
great prognostic potential; however, its additive value
on top of established clinical factors has yet to be
deﬁned.
TRANSLATIONAL OUTLOOK: T1 mapping has the
potential toprovide insights intopathogenic processes,
detect diseases at a very early stage, noninvasively
monitor disease progress, or even guide therapy.
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22single center are (1) adherence to a constant clinical
routine, (2) constant quality of work-up, and (3)
constant follow-up.
With regard to myocardial biopsy, it has to be
noted that during left-sided heart catheterization,
only small myocardial specimens can be retrieved.
The distribution and extent of extracellular matrix
in such specimens does not necessarily reﬂect extra-
cellular matrix expansion across the entire LV
myocardium. However, we found a signiﬁcant corre-
lation between ECV on CMR T1 mapping and histo-
logical ECV.
The majority of our patients (85%) presented
with normal or preserved LV systolic function (LV
ejection fraction >50%). Our results may therefore
not be transferable to other patient populations with
reduced LV function.
Studies based on T1-mapping results are further-
more limited by the lack of a standardized T1-
mapping approach. In the present study, we used
one of the standard T1-mapping sequences (see the
Methods section).
CONCLUSIONS
CMR T1 mapping is a promising technique that allows
accurate estimation of the extent of myocardial
extracellular matrix expansion compared withbiopsies. Among imaging parameters, CMR-ECV has
great prognostic potential; however, its additive
value in conjunction with established clinical factors
has yet to be deﬁned.
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